Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Betamethasone Dipropionate Patent Expiration

Betamethasone Dipropionate is Used for treating plaque psoriasis. It was first introduced by Schering Corp Sub Schering Plough Corp in its drug Diprosone on Approved Prior to Jan 1, 1982. Other drugs containing Betamethasone Dipropionate are Alphatrex, Diprolene Af, Betamethasone Dipropionate, Diprolene, Sernivo. 25 different companies have introduced drugs containing Betamethasone Dipropionate.


Betamethasone Dipropionate Patents

Given below is the list of patents protecting Betamethasone Dipropionate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sernivo US10179137 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms
Sernivo US9364485 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms
Sernivo US9433630 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms
Sernivo US9439911 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms
Sernivo US9655907 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms
Sernivo US9775851 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms
Sernivo US9877974 Topical formulations comprising a steroid Aug 31, 2030 Primus Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Betamethasone Dipropionate's patents.

Given below is the list recent legal activities going on the following patents of Betamethasone Dipropionate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 06 Mar, 2024 US9433630
Payment of Maintenance Fee, 8th Yr, Small Entity 14 Dec, 2023 US9364485
Payment of Maintenance Fee, 4th Yr, Small Entity 15 Jul, 2022 US10179137
Payment of Maintenance Fee, 4th Yr, Small Entity 30 Jul, 2021 US9877974
Email Notification
Critical
26 Apr, 2021 US10179137
Change in Power of Attorney (May Include Associate POA)
Critical
26 Apr, 2021 US10179137
Correspondence Address Change
Critical
22 Apr, 2021 US10179137
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 22 Apr, 2021 US10179137
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 21 Apr, 2021 US9877974
Change in Power of Attorney (May Include Associate POA)
Critical
21 Apr, 2021 US9877974


Betamethasone Dipropionate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Betamethasone Dipropionate Generic API Manufacturers

Several generic applications have been filed for Betamethasone Dipropionate. The first generic version for Betamethasone Dipropionate was by Actavis Mid Atlantic Llc and was approved on Jul 31, 1985. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Apr 10, 2024.

Given below is the list of companies who have filed for Betamethasone Dipropionate generic, along with the locations of their manufacturing plants worldwide.